Management of oligometastatic non-small cell lung cancer patients: Current controversies and future directions

Table 2 Publishes results for stereotactic body radiation therapy-treated liver metastases

Study	Number of lesions	Patients, n	Primary tumor	Dose/fractions	Toxicity	Mean follow-up, mo	Control, local	Survival
Blomgren et al[74]	Variable	31	Various	8-66 Gy/1-4	2 Hemorrhagic gastritis	1.5-3.8	80%	Not reported
Hoyer et al[75]	1-6 (< 6 cm)	44	Various	45 Gy/3	1 liver failure 2 severe GI toxicity	52	2-yr: 86%	1-yr: 67% 2-yr: 38%
Mendez Romero et al[76]	1-3 (< 7 cm)	25	Various	37.5 Gy/3	4 acute grade ≥ 3 1 late grade 3	12.9	2-yr: 86%	1-yr: 85% 2-yr: 62%
Rusthoven et al[7]	1-3 (< 6 cm)	47	Various	60 Gy/3	< 2% late	16	2-yr: 92% < 3 cm: 100%	mean, 17.6 mo
Lee et al[77]	Variable	68	Various	28-60 Gy/3	Acute: 8 GIII, 1 GIV	10.8	1-yr: 71%	18 m: 47%
Ambrosino et al[78]	1-3 (< 6 cm)	27	Various	25-60 Gy/3	Not reported	13	74%	Not reported
Goodman et al[79]	1-5 (< 5 cm)	26	Various	18-30 Gy/1	Late: 4 GII	17.3	1-yr: 77%	1-yr: 62% 2-yr: 49%
Rule et al[80]	1-5	27	Various	30 Gy/3 50-60 Gy/5	No ≥ G2	20	30 Gy: 56% 50 Gy: 89%60 Gy: 100%	30 Gy: 56% at 2-yr 50 Gy: 67% at 2-yr 60 Gy: 50% at 2-yr
Scorsetti et al[81]	1-3 (< 6 cm)	61	Various	52.5-75/3	No ≥ G3	24	91%	1-yr: 80%2-yr: 70%
Mahadevan et al[70]	Variable	427	Various	45 (12-60) / 3 (1-5)	Not reported	14 (1-91)	Median: 52 mo 1-yr: 84%2-yr: 72%	Mean: 22 mo 1-yr: 74% 2-yr: 49%

GI: Gastrointestinal.